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Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster —
Nebraska, November–December 2021
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Peter C. Iwen, PhD5; Joseph Fauver, PhD6; Bryan Buss, DVM1,7; Matthew Donahue, MD1

On December 28, 2021, this report was posted as an MMWR
Early Release on the MMWR website (https://www.cdc.gov/mmwr).
The B.1.1.529 (Omicron) variant of SARS-CoV-2 (the
virus that causes COVID-19) was first detected in specimens collected on November 11, 2021, in Botswana and on
November 14 in South Africa;* the first confirmed case of
Omicron in the United States was identified in California
on December 1, 2021 (1). On November 29, the Nebraska
Department of Health and Human Services was notified of
six probable cases† of COVID-19 in one household, including one case in a man aged 48 years (the index patient) who
had recently returned from Nigeria. Given the patient’s travel
history, Omicron infection was suspected. Specimens from all
six persons in the household tested positive for SARS-CoV-2
by reverse transcription–polymerase chain reaction (RT-PCR)
testing on December 1, and the following day genomic
sequencing by the Nebraska Public Health Laboratory identified an identical Omicron genotype from each specimen
(Figure). Phylogenetic analysis was conducted to determine
if this cluster represented an independent introduction of
Omicron into the United States, and a detailed epidemiologic
investigation was conducted. This activity was reviewed by
CDC and was conducted consistent with applicable federal
law and CDC policy.§
The index patient, who was unvaccinated, had a history of
domestically acquired symptomatic SARS-CoV-2 infection confirmed by RT-PCR a year prior in November 2020. He reported
unmasked close contact¶ with a masked, coughing person on
November 20, 2021, during an international conference in
Nigeria, which included attendees from multiple African countries. Before his return trip to the United States, he completed
required pretravel testing with receipt of a negative antigen test
result on November 21. Upon his return on November 23, while
still asymptomatic, he had unmasked close contact with five
household contacts. One household contact was fully vaccinated**
* https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientificbrief-omicron-variant.html
† https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/
§ 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect.
552a; 44 U.S.C. Sect. 3501 et seq.
¶ https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantineisolation.html#closecontact
** https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19vaccines-us.html#:~:text=A%20person%20is%20considered%20fully,for%20
fully%20vaccinated%20people
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(second Pfizer-BioNTech vaccine dose received in August 2021)
and had previous symptomatic COVID-19 (RT-PCR confirmed
in November 2020), three were unvaccinated and had previous
symptomatic COVID-19 (RT-PCR confirmed in November
2020), and one was unvaccinated and had mild upper respiratory symptoms in November 2020, just before illness onset in the
other household members, but received a negative SARS-CoV-2
RT-PCR test result at that time. No household members reported
underlying medical conditions or immunocompromising conditions known to increase the risk for severe COVID-19 or diminish
response to vaccination.††
On November 24, 2021, the index patient experienced
symptoms consistent with COVID-19§§ and initially received
a positive SARS-CoV-2 antigen test result from a local medical center on November 26. All six household members
(median age = 18.5 years; range = 11–48 years) experienced symptom onset during November 24–26; median interval between
earliest possible exposure to the index patient and symptom onset
was 73 hours (range = 33–75 hours). The index patient and the four
household contacts with previous confirmed infections described
the symptoms and severity of their recent COVID-19 infection as
being similar to or milder than those during their first infection.
The five reinfected patients experienced fewer current symptoms,
including loss of taste (none), loss of smell (none), and subjective
fever (two), compared with symptoms reported during their first
infections (four, four, and four, respectively). The unvaccinated
patient without a previous COVID-19 diagnosis experienced
cough, joint pain, congestion, fever, and chills. None required
hospitalization for either their first or second infections. Twelve close
community contacts of the family were identified. Four consented
to testing for SARS-CoV-2 (median of 10.5 days postexposure;
range = 10–11 days); specimens from these four close contacts
tested negative.
Epidemiologic and clinical features of Omicron infection are
still being described. Observations from this investigation, which
included one patient who experienced reinfection¶¶ after having
been fully vaccinated, four patients who experienced reinfection,
††

https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/peoplewith-medical-conditions.html
§§ Abdominal pain, diarrhea, fatigue, headache, muscle aches, chest pressure,
chills, subjective fever, cough, runny nose, sore throat, and dizziness.
¶¶ https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-20192021/#:~:text=The%20following%20should%20be%20enumerated%20
as%20a%20new%20case
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FIGURE. Global phylogeny of B.1.1.529 (Omicron) samples available on Global Initiative on Sharing All Influenza Data* as of December 6, 2021
(650 total genomes) (A) and expanded view of Omicron sequences† (B) — Nebraska, November–December 2021§,¶,**,††,§§
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Abbreviation: SNP = single nucleotide polymorphism.
* https://www.gisaid.org
† Branch lengths are shown in number of mutations from the root. The maximum-likelihood phylogenetic trees are rooted with the original SARS-CoV-2 genome
Wuhan/Hu-1/2019.
§ Each of the six SARS-CoV-2 genomes generated from this cluster is >94% complete and shares 100% nucleotide identity across the length of the genome, consistent
with household transmission.
¶ Genomes from the five secondary cases have SNPs at nucleotide positions T1552C and C23709T that are not yet found in other Omicron genomes sampled.
** The genome from the index patient, NCOV21-42615, has the ambiguous nucleotide “N” at positions 1552 and 23709 and further inspection of the read-level data
showed nucleotide variability at both sites. The SNP allele frequency at these sites in the NCOV21-42615 genome is >50%, consistent with epidemiologic findings
of household transmission from the index patient to all secondary cases.
†† https://academic.oup.com/bioinformatics/article/34/23/4121/5001388
§§ https://onlinelibrary.wiley.com/doi/full/10.1111/2041-210X.12628
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and one who experienced their first infection, suggest a shorter
incubation period and a clinical syndrome similar to or milder
than that associated with previously described variants in persons
who have been vaccinated or previously infected, and add to
existing evidence suggesting an increased potential for reinfection.*** Whereas the median SARS-CoV-2 incubation period
has been described as ≥5 days (2,3), and closer to 4 days for the
SARS-CoV-2 B.1.617.2 (Delta) variant,††† the median incubation period§§§ observed in this cluster was approximately 3 days.
Although few clinical descriptions of Omicron infections are available, mild illness among vaccinated patients has been reported (4).
It is unknown whether the mild clinical syndromes or differing
symptom descriptions are a result of existing immunity or altered
clinical features associated with Omicron infection. The five reinfections, including one after full vaccination, might be explained
by waning immunity, the potential for partial immune evasion by
Omicron, or both. Conclusions drawn from these observations
are limited by small sample size. More data will be needed to fully
understand the epidemiology of the Omicron variant.
Travel history of the index patient and phylogenetic analysis of
the secondary cases indicate an international introduction of the
Omicron variant, consistent with other early cases identified in
the United States (1). The recent emergence of Omicron, which is
now projected to be the dominant variant in the United States,¶¶¶
reinforces the importance of vaccination, in coordination with other
prevention strategies (e.g., masking and physical distancing), to
protect people from COVID-19, slow transmission, and reduce the
likelihood of new variants emerging. In addition, the rapid identification and epidemiologic characterization of this cluster underscore
the importance of robust and timely genomic surveillance to detect
and respond to emerging SARS-CoV-2 variants of concern.
*** https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2
††† https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v2
§§§ Incubation period is defined as the interval from earliest possible exposure
of household contacts to the index patient until symptom onset.
¶¶¶ https://covid.cdc.gov/covid-data-tracker/#variant-proportions
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